Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 35 (December 10), 2006: pp. 5552-5564
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.08.2073

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitra, A. P.
Right arrow Articles by Cote, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitra, A. P.
Right arrow Articles by Cote, R. J.

REVIEW ARTICLE

Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification

Anirban P. Mitra, Ram H. Datar, Richard J. Cote

From the Departments of Pathology and Urology, University of Southern California Keck School of Medicine, Los Angeles, CA

Address reprint requests to: Richard J. Cote, MD, FRCPath, USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033; e-mail: cote_r{at}ccnt.hsc.usc.edu

Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by interacting with the Ras–mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.

Supported in part by National Institutes of Health Grants No. CA-70903, CA-14089, CA-86871, and CA-103455, and National Cancer Institute Grant CA-71921.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
S. K. Kang, Y. K. Chae, J. Woo, M. S. Kim, J. C. Park, J. Lee, J. C. Soria, S. J. Jang, D. Sidransky, and C. Moon
Role of Human Aquaporin 5 In Colorectal Carcinogenesis
Am. J. Pathol., August 1, 2008; 173(2): 518 - 525.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. P. Singh, A. Tyagi, G. Sharma, S. Mohan, and R. Agarwal
Oral Silibinin Inhibits In vivo Human Bladder Tumor Xenograft Growth Involving Down-Regulation of Survivin
Clin. Cancer Res., January 1, 2008; 14(1): 300 - 308.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. F. Bajorin, R. J. Motzer, and G. J. Bosl
Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research
J. Clin. Oncol., December 10, 2006; 24(35): 5479 - 5481.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online